A Phase 2 interventional study of LAI plus multi-drug regimen in Mycobacterium Infections, Nontuberculous and Mycobacteria, Atypical, sponsored by Kevin Winthrop. Completed at 2 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.
Sponsored by Kevin Winthrop · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Mycobacterium Infections, Nontuberculous · United States.
Among the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States, this one is the 14th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2016, is one of 10 in phase 2, and was the 9th registered.
54 studies on the registry are indexed under Mycobacterium Infections, Nontuberculous; 19 are open to participants now.
Browse Mycobacterium Infections, Nontuberculous studies →7 of the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States are open now. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18+
Kevin Winthrop · Sites in United States
Ages 18+
Nancy Klimas · Sites in United States
Ages 18–70
Chris Goss · Sites in United States
Ages 18+
Oregon Health and Science University · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Mycobacterium Infections, Nontuberculous studies recruiting now, 8 (67%) set no upper age limit and 2 (17%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 4 · Phase 4 1
First in 1992; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 40 across 35 interventional studies indexed under Mycobacterium Infections, Nontuberculous.
Median enrollment 58 across the 18 interventional studies, 125 across the 4 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 24 have an industry lead sponsor. The 10 most frequent:
Kevin Winthrop is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Kevin Winthrop has 3 studies filed under Mycobacterium Infections, Nontuberculous — fewer than ten, so there is no comparison to draw.
4 of the studies in Mycobacterium Infections, Nontuberculous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06262282National Jewish HealthMycobacteriophage Treatment of Non-tuberculosis Mycobacteria | 2026-12-31 |
| NCT04921943Oregon Health and Science UniversityHypertonic Saline for MAC | 2027-01-20 |
| NCT04294043Chris GossIV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study) | 2027-03-31 |
| NCT07021794Nancy KlimasSARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID) | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed study will assess the efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines, for treatment of mycobacterium abscessus lung disease.
This is an open-label study of efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI), in addition to a standard multi-drug antibiotic therapy in accordance with the 2007 ATS/ IDSA guidelines, in patients with Mycobacterium abscessus lung disease. The multi-drug therapy is determined at the discretion of the Investigator. After screening, all eligible patients will enter the trial and will receive LAI 590 mg once daily for 12 months. If deemed necessary by the investigator, dose may be adjusted from a minimum of three times per week up to daily, in cases of adverse events relating to tolerability.
All patients who enter the study will have subsequent study visits at Months 1,2,4,6,9, at End-of-Study or Month 12, and at 1 and 3 months post study drug discontinuation. At each visit (including screening), review of concomitant medications, review of adverse events, and physical exam, will be performed. Chest CT scan will be performed at baseline, 6 months, and 12 months, unless a chest CT scan has already been performed within 6 months on this time point. The 6 minute walk test and QOL-B-NTM will be performed at baseline, 6 months, 12 months, and 3 months post study drug discontinuation. All patients will have inducted sputum collected at each study visit, and patients will self-collect expectorated sputum during intervening monthly time-points until study completion to determine changes in mycobacterial smear and culture status.
Unscheduled visits will occur as needed should subjects' symptoms worsen between visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
Drug: LAI plus multi-drug regimen
Drug page: AmikacinStudies of AmikacinAmikacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
Also known as: ARIKAYCE™
Change from Baseline sputum culture at 12 months
Time frame: Sputum examined for culture change from Baseline at 12 months
Change from Baseline 6-minute Walk Test at 6 months
Time frame: 6-minute Walk Test results examined for change from Baseline at 6 months
Change from Baseline 6-minute Walk Test at 12 months
Time frame: 6-minute Walk Test results examined for change from Baseline at 12 months
Change from End of Treatment (EOT) sputum culture at 3 months post EOT
Time frame: Sputum examined for culture change from EOT at 3 months post EOT
Number of Hospitalizations for pulmonary exacerbations
Time frame: Number of Hospitalizations for pulmonary exacerbations that occur between Baseline and 12 months
Number of Adverse Events
Time frame: Number of Patient-reported and Investigator-reported Adverse Events at 12 months
Number of subjects discontinuing study drug due to Adverse Event
Time frame: Number of subjects who discontinue study drug before 12 months due to Adverse Event will be examined at 12 months
Change from Baseline reported nontuberculous mycobacterium (NTM) symptoms at End of Treatment (EOT)
Time frame: Patient-reported NTM symptoms examined for change from Baseline at EOT (12 months)
Change from Baseline Chest CT at End of Treatment (EOT)
Time frame: CT scan examined for change from Baseline at EOT (12 months)
Change from Baseline body weight at End of Treatment (EOT)
Time frame: body weight of patient examined for change from Baseline at EOT (12 months)
Change from Baseline Body Mass Index (BMI) at End of Treatment (EOT)
Time frame: BMI of patient examined for change from Baseline at EOT (12 months)
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2016 to primary completion in Oct 2019, 36 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amikacin
Mycobacterium Infections, Nontuberculous →
Kevin Winthrop